Ascendis Pharma (ASND) is back in focus after releasing Week 52 topline data from its COACH Phase 2 trial, in which once weekly TransCon CNP plus TransCon hGH in children with achondroplasia showed durable growth and maintained a consistent safety profile.

The COACH data arrive at a time when Ascendis Pharma’s share price sits at US$208.75, after a 6.16% 1 month share price return but a slightly negative year to date move. The 1 year total shareholder return of 55.29% and 3 year total shareholder return of 77.04% point to momentum that has been building over a longer horizon, supported by continued clinical progress and upcoming investor events such as the J.P. Morgan Healthcare Conference.

If this kind of rare disease progress interests you, it could be a good moment to scan other opportunities among healthcare stocks and see what else catches your eye.

With the stock at US$208.75, sitting on a 55.29% 1 year total return and trading at a discount to analyst targets and intrinsic estimates, is Ascendis still offering upside, or is the market already pricing in future growth?

Most Popular Narrative: 19% Undervalued

With Ascendis Pharma last closing at US$208.75 and the most followed narrative pointing to a fair value of US$257.66, the gap between price and expectations is clear enough to dig into what is driving that view.

Regulatory progress and pipeline advancement, such as the priority review for TransCon CNP in achondroplasia and positive combination trial results, are paving the way for new blockbuster therapies and potential multi-billion EUR peak sales opportunities, enhancing future revenue growth and reducing revenue concentration risk.

Want to see what sits behind that valuation gap? Revenue growth projections, margin lift and a premium future earnings multiple are all baked into this story. Curious which assumptions really move the fair value needle here? Read on to unpack the full narrative.

Result: Fair Value of $257.66 (UNDERVALUED)

However, this hinges on continued strength from SKYTROFA and YORVIPATH. Any setbacks in TransCon CNP approvals or competitive data could quickly challenge the current growth story.

Build Your Own Ascendis Pharma Narrative

If you see the story differently, or prefer to test the numbers yourself, you can build a fresh Ascendis view in minutes with Do it your way

A great starting point for your Ascendis Pharma research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.

Looking for more investment ideas?

If Ascendis has caught your attention, do not stop here. Broaden your watchlist with a few more focused ideas that could sharpen your next move.

• Spot potential value stories early by scanning these 872 undervalued stocks based on cash flows that may be trading below what their cash flows suggest.
• Capture growth themes by checking out these 28 AI penny stocks tied to artificial intelligence trends across different parts of the market.
• Strengthen your income prospects by reviewing these 11 dividend stocks with yields > 3% that already offer yields above 3%.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.